Tel-Aviv based start-up Aidoc, a leading provider of Artificial Intelligence solutions for radiologists, received US Food and Drug Administration (FDA) clearance for its AI solution that spots strokes (Large-Vessel Occlusion) in the brain during head CTA scans.An LVO is the blockage of vessels in the brain, and according to Ariella Shoham, Aidoc's vice president of marketing, the AI technology "uses deep learning to automatically look at every head CT before a patient has even left the imaging room. "It investigates the images to see if they show blocked blood vessels in the brain or bleeding (intracranial hemorrhages)," she explained. "If one of these time-critical conditions is found, Aidoc re-prioritizes the worklists of radiologists so that the urgent scan is looked at immediately and the patient can be treated quickly."Shoham said that Aidoc already received FDA clearances to identify and flag pulmonary embolism (blockages in the lungs) and cervical spine fractures (broken neck). "Other Aidoc solutions currently in clinical testing include identifying air in the abdomen," she continued. "Altogether, Aidoc is targeting the most common critical life-threatening conditions that make up 80% of all urgent cases on CT scans.
Aidoc announced today that the US Food and Drug Administration (FDA) has given regulatory clearance for the commercial use of its triaging and notification algorithms for flagging and communicating incidental pulmonary embolism . Flagging incidental, critical findings is a huge technical challenge due to the varied imaging protocols used and lower incidences of such cases. The ability to prioritize incidental critical conditions accurately is a breakthrough in the value AI can bring to the radiologist workflow. "The most common use case we experienced is for critical unsuspected findings in oncology surveillance patients" said Dr. Cindy Kallman, Chief, Section of CT at Cedars-Sinai Medical Center. "The ability to call the referring physician while the patient is still in the house is huge. We are essentially offering a point-of-care diagnosis of PE for our outpatients. Our referring physicians have been completely wowed by this."
LucidHealth, a physician-owned and led radiology company, announced today that it is using an AI-powered diagnostic aid from leading AI vendor Aidoc to help prioritize and expedite treatment to patients with critical, life-threatening conditions. LucidHealth is one of the first radiology companies in the Midwest to incorporate artificial intelligence (AI) into its radiology practice, further cementing their commitment to continuously improving patient outcomes. "LucidHealth is committed to bringing the most advanced, highest quality technological solutions to assist our patients," said Mark Alfonso, M.D., chief medical officer, LucidHealth. "Aidoc's AI-powered alerting system combined with our own proprietary workflow software, RadAssist, enables us to prioritize the patients with the most urgent, time-critical, life-threatening conditions. For example, proactive examination for intracranial hemorrhages via AI automatically and immediately flags those cases to the radiologists, allowing them to prioritize and assist in addressing those patients sooner. This reduction in wait time could be life-altering; providing the ability to ensure rapid radiologist inspection and triage for expedited treatment."
Israeli radiology startup Aidoc has received FDA clearance for its AI-based product meant to help identify potential cases of pulmonary embolism in chest CT scans. Pulmonary embolism (PE) – which occurs when a blood clot gets lodged in the lung – is considered a silent killer that causes up to 200,000 deaths a year in the United States. The condition often strikes with little to no warning and diagnosis of a case can be extremely time-sensitive. Aidoc's technology doesn't require dedicated hardware and runs continuously on hospital systems, automatically ingesting radiological images. The 70-person company focuses on workflow optimization in radiology to help triage high risk patients for additional and faster review.
Highlighting the company's rapid progress in the radiology space, Israeli startup Aidoc has received its third FDA clearance for its AI-based algorithm to help highlight potential instances of cervical spinal fractures. The regulatory decision comes just a few weeks after the FDA cleared the company's pulmonary embolism product. Aidoc also has approval for its algorithm for the detection of intracranial hemorrhages through CT scans. The company's cervical spinal fracture product already received approval from European regulators. Delayed diagnosis of cervical spinal fracture is a common problem in emergency rooms and can lead to potential major neurological issues including quadriplegia.